Type 2 Diabetes Clinical Pipeline | 75+ Companies, Including Celon Pharma, Sciwind Biosciences, and AstraZeneca, Advancing the Next Generation of Breakthrough Therapies

The Type 2 Diabetes market is evolving with cutting-edge research and new therapeutic advancements.

DelveInsight's 'Type 2 Diabetes Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Type 2 Diabetes therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Type 2 Diabetes pipeline domain.

For Type 2 Diabetes emerging drugs, the Type 2 Diabetes pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Type 2 Diabetes Pipeline Report
• DelveInsight's Type 2 Diabetes Pipeline analysis depicts a robust space with 75+ active players working to develop 80+ pipeline drugs for Type 2 Diabetes treatment.
• The leading Type 2 Diabetes companies include Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Regor Pharmaceuticals Inc., Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc, and others are evaluating their lead assets to improve the Type 2 Diabetes treatment landscape.
• Key Type 2 Diabetes pipeline therapies in various stages of development include NRDN-101, ECC5004, KN056, XW014, RGT001-075, HR17031, CPL207280, THDB0206, LY-3209590, Insulin icodec, and others.
• In February 2025, Tandem Diabetes Care announced FDA clearance of its Control-IQ+ automated insulin delivery algorithm for type 2 diabetes patients.
• In February 2025, Sotagliflozin, FDA-approved for type 2 diabetes and kidney disease, was shown to significantly reduce heart attack and stroke risk in high-risk patients, offering a new treatment for cardiovascular protection.
• In January 2025, the FDA approved a new indication for semaglutide to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease, according to Novo Nordisk.
• In December 2024, the FDA approved the first generic version of Victoza (liraglutide injection) for adults and pediatric patients over 10 with type 2 diabetes, according to a recent news release.

Request a sample and discover the recent breakthroughs happening in the Type 2 Diabetes pipeline landscape @ https://www.delveinsight.com/report-store/type-2-diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Type 2 Diabetes Overview
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder that affects how the body regulates blood sugar (glucose). It is primarily characterized by insulin resistance, where the body's response to insulin becomes impaired. Initially, this resistance is countered by an increase in insulin production to maintain glucose balance, but over time, insulin secretion declines, leading to persistent hyperglycemia and the onset of T2DM. While the condition is most commonly diagnosed in individuals over 45 years old, the prevalence is rising among children, adolescents, and younger adults due to increasing obesity rates, sedentary lifestyles, and high-calorie diets.

T2DM involves both insulin resistance and beta-cell dysfunction. In the early stages, pancreatic beta cells compensate by increasing insulin secretion to keep blood sugar levels within a normal range. However, as the disease progresses, beta-cell function deteriorates, leading to inadequate insulin production and sustained hyperglycemia. Most individuals with T2DM are overweight or have excess abdominal fat, which contributes to insulin resistance through inflammatory mechanisms, increased free fatty acid (FFA) release, and adipokine dysregulation. Additional risk factors include physical inactivity, a history of gestational diabetes mellitus (GDM), hypertension, and dyslipidemia. Emerging research highlights the role of adipokine imbalances, chronic inflammation, incretin hormone abnormalities-such as reduced glucagon-like peptide-1 (GLP-1) activity-hyperglucagonemia, increased renal glucose reabsorption, and gut microbiota alterations in the pathophysiology of T2DM.

Diagnosis of T2DM is typically confirmed through tests such as fasting plasma glucose (FPG), A1C, random plasma glucose (RPG), and the oral glucose tolerance test (OGTT). An A1C level below 5.7% is considered normal, while FPG levels should be under 99 mg/dL, and OGTT readings should remain below 139 mg/dL. Managing T2DM involves a combination of lifestyle modifications-including diet and physical activity-along with medications to control blood sugar and prevent complications. Common drug classes include metformin, sulfonylureas, meglitinides, DPP-4 inhibitors, thiazolidinediones, alpha-glucosidase inhibitors, SGLT2 inhibitors, and bile acid sequestrants. In September 2019, the U.S. Food and Drug Administration (FDA) approved Rybelsus (semaglutide) oral tablets to help improve blood sugar control in adults with type 2 diabetes when used alongside diet and exercise.

Find out more about Type 2 Diabetes medication @ https://www.delveinsight.com/report-store/type-2-diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Type 2 Diabetes Treatment Analysis: Drug Profile
LY-3209590: Eli Lilly and Company
Insulin efsitora alfa (LY3209590) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. Efsitora is in phase III development for adults with type 1 and 2 diabetes.

THDB0206: Tonghua Dongbao Pharmaceutical
BC Lispro (THDB0206) is an ultra-rapid-acting insulin analog developed by Tonghua Dongbao Pharmaceutical Co., Ltd. for the treatment of type 2 diabetes. BC Lispro is designed to restore early-phase insulin secretion, which is often impaired in diabetic patients. This insulin analog utilizes a new formulation technology that allows for rapid absorption and action, mimicking the physiological pattern of insulin secretion after meals. Such characteristics are expected to reduce the risk of late postprandial hypoglycemia, providing patients with greater flexibility in managing their insulin injections. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Type 2 Diabetes.

HU6: Rivus Pharmaceuticals
Rivus Pharmaceuticals is developing HU6, a novel oral medication classified as a Controlled Metabolic Accelerator (CMA), to treat various metabolic diseases, including type 2 diabetes. HU6 works by leveraging mitochondrial uncoupling to increase the body's resting metabolic rate, promoting fat loss while preserving lean muscle mass. Currently, the drug is in the Phase II stage of development to treat Type 2 Diabetes.

Key Type 2 Diabetes Therapies and Companies
• Tirzepatide /LY3298176: Eli Lilly and Company
• Danuglipron: Pfizer
• LY-3209590: Eli Lilly and Company
• HU6: Rivus Pharmaceuticals
• THDB0206: Tonghua Dongbao Pharmaceutical
• AZD5004: AstraZeneca
• XW014: Sciwind Biosciences
• KN056: Suzhou Alphamab Co., Ltd.

Learn more about the novel and emerging Type 2 Diabetes pipeline therapies @ https://www.delveinsight.com/report-store/type-2-diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Type 2 Diabetes Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Type 2 Diabetes Pipeline Report
• Coverage: Global
• Key Type 2 Diabetes Companies: Tonghua Dongbao Pharmaceutical, Eli Lilly and Company, Rivus Pharmaceuticals, Celon Pharma, Sciwind Biosciences, AstraZeneca, Suzhou Alphamab Co., Ltd., Neurodon, Abarceo Pharma, Chong Kun Dang Pharmaceutical, Regor Pharmaceuticals Inc., Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova, Sparrow Pharmaceuticals, HighTide Biopharma Pty Ltd, Novo Nordisk A/S, Biomea Fusion Inc, and others.
• Key Type 2 Diabetes Pipeline Therapies: NRDN-101, ECC5004, KN056, XW014, RGT001-075, HR17031, CPL207280, THDB0206, LY-3209590, Insulin icodec, and others.

Dive deep into rich insights for drugs used for Type 2 Diabetes treatment; visit @ https://www.delveinsight.com/report-store/type-2-diabetes-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Type 2 Diabetes Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Type 2 Diabetes Pipeline Therapeutics
6. Type 2 Diabetes Pipeline: Late-Stage Products (Phase III)
7. Type 2 Diabetes Pipeline: Late-Stage Products (Phase III)
8. Type 2 Diabetes Pipeline: Mid-Stage Products (Phase II)
9. Type 2 Diabetes Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.